REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
12/01/2025
Back to search
Official data from USPTO
XELLERA THERAPUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Quick snapshot
ST13
US500000088977235Class
9, 10, 40, 42, 44
Filing
88977235
Registration
6211225
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
12/02/2025
Trademark type
Combined
Nice classes
9, 10, 40, 42, 44
Filing date
05/27/2019
Registration date
12/01/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/01/2020
Last transaction
12/02/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
5
Owner type
99
Owner location
HUNG HOM, KLN, HK
Examiner
KAPLAN,VALERIE ELIZABETH
Law office
L70
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording "Xellera Theraputics" in a stylized font.
Holders and representatives
Holders
XELLERA THERAPEUTICS LIMITED
Representatives
Kevin O'Keefe
Technical classification
Nice Classes
Class 9Class 10Class 40Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 9
bioreactor for cell culturing; Bioreactors for laboratory use; Research laboratory analyzers for measuringtesting and analyzing blood and other bodily fluids; Computer-controlled electronic apparatus for electrophysiological measurement and testing of cells
Class 10
Apparatus for the regeneration of stem cells for medical purposes; Medical apparatus and instrument for diagnostic useapparatus for medical diagnostic testing in the fields of cancer or other tissue-based diagnostic testingcytology and cell-based testing; Medical apparatus and instruments for treating cardiovascular disease; Medical apparatus for introducing pharmaceutical preparations into the human body; Medical diagnostic apparatus for testing blood antigens and antibodies
Class 40
Biomanufacturing for othersmanufacturing of pharmaceuticals using biological organisms in the manufacturing process; Contract manufacturing in the field of biotechnology; Cryogenic preservation; Cryopreservation of human tissue; Custom manufacture of biopharmaceuticals by pharmaceutical compounders; Manufacture of pharmaceuticals to order and/or specification of others; Manufacturing services for others in the field of stem cells; Providing technical information in the field of pharmaceutical manufacturing
Class 42
Biological research; Biomedical research services; Biotechnology research; Chemical research; Conducting clinical trials for others; Conducting early evaluations in the field of new pharmaceuticals; Development of pharmaceutical preparations and medicines; Drug discovery services; Industrial research in the field of regenerative and reparative therapies; Medical laboratory services; Medical research; Pharmaceutical drug development services; Pharmaceutical research services; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development in the pharmaceutical and biotechnology fields; Research and development of new products for others; Research and development of vaccines and medicines; Scientific research; Scientific research and development; Scientific research in the field of gene therapy; Stem cell research services; Technology research in the field of regenerative and reparative therapies
Class 44
Blood bank services; Health care servicesregenerative and reparative therapies; Human tissue bank services; Medical care; Medical services; Medical services in the field of regenerative and reparative therapies; Medical testing for diagnostic or treatment purposes in the field of regenerative and reparative therapies; Organ and tissue bank services; Stem cell therapy services
Publications
History of USPTO decisions and trademark events.
31 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/08/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/08/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/08/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
12/01/2020
CORV
REVIEW OF CORRESPONDENCE COMPLETE
10/29/2020
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
10/29/2020
IUCN
NOTICE OF ALLOWANCE CANCELLED
10/07/2020
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
10/07/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
06/23/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/28/2020
PUBO
PUBLISHED FOR OPPOSITION
04/28/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/08/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/25/2020
DPCC
DIVISIONAL PROCESSING COMPLETE
03/25/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
03/24/2020
ALIE
ASSIGNED TO LIE
02/27/2020
DRRR
DIVISIONAL REQUEST RECEIVED
02/23/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/23/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/23/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/23/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/23/2020
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
02/23/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/31/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/31/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/22/2019
GNRT
NON-FINAL ACTION E-MAILED
08/22/2019
CNRT
NON-FINAL ACTION WRITTEN
08/22/2019
DOCK
ASSIGNED TO EXAMINER
08/15/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/11/2019
NWAP
NEW APPLICATION ENTERED
05/30/2019
Continuous trademark protection
Get notified about every new filing that threatens XELLERA THERAPUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.